Abstract：Objective：To analyze the mechanism of Renshen Yizhi Jiannao Prescription in treating Alzheimer's disease（AD）. Methods：The active components of Renshen Yizhi Jiannao Prescription were retrieved from the TCMSP platform， and their targets were corrected using the Uniprot database. Gene targets for AD were retrieved from the Genecard database，and duplicate genes were removed. The intersection of drug targets and disease targets was taken to obtain potential targets for Renshen Yizhi Jiannao Prescription in treating AD. The STRING database was used for protein-protein interaction（PPI）network analysis of key targets. GO and KEGG pathway enrichment analyses were performed using R language，and the effective compound-target network was constructed using Cytoscape software. The effect of different concentrations of Renshen Yizhi Jiannao Prescription extract on the survival rate of BV-2 glial cells was detected. Western blot was used to detect the expression of p-p38，p38，p-p65，and p65 proteins in BV-2 cells. Results： A total of 47 potential active components of Renshen Yizhi Jiannao Prescription were identified， acting on 360 targets. For AD， 14 407 targets were identified， with 303 potential therapeutic targets. Quercetin， kaempferol， m-hydroxybenzoic acid，and ginseng oside were identified as potential key components，while MAPK1，TP53，JUN， and TNF were identified as potential key targets. GO functional analysis suggested that cellular inflammation，oxidative stress， neuronal apoptosis， and DNA signal transcription might be the biological pathways through which Renshen Yizhi Jiannao Prescription exerts its effects on AD. KEGG pathway enrichment analysis identified 172 pathways，mainly including lipid and atherosclerosis， as well as AGE-RAGE， IL-17， and TNF signaling pathways in diabetic complications. In vitro experiments showed that Renshen Yizhi Jiannao Prescription could inhibit the expression of p-p38 and p-p65 proteins in LPS-activated BV-2 glial cells. Conclusion： Renshen Yizhi Jiannao Prescription has the characteristics of multiple components，multiple targets，and multiple signaling pathways in treating AD. Its mechanism of action can be related to the inhibition of MAPK and NF-κB signaling pathways and the reduction of neuroinflammation.